ea0089c9 | Clinical – Chemo/SSA/Biologics | NANETS2022
Lee Patrick C
, Blais Edik M
, Gong Jun
, Osipov Arsen
, Moshayedi Natalie
, Thomassian Shant
, Ng Camille
, Chuy Jennifer
, Matrisian Lynn M
, Petricoin III Emanuel F
, Pishvaian Michael J
, Hendifar Andrew E
Background: Capecitabine and temozolomide (CAPTEM) is a common regimen for the treatment of metastatic, well-differentiated pancreatic neuroendocrine tumors (PNETs). However, it is unknown whether certain genomic profiles predict response to CAPTEM. PNETs often contain mutations in MEN1, ATRX, DAXX, and the PI3K/AKT/mTOR pathway. We sought to determine whether the mutational status of these genes may correlate with progression-free survival (PFS) on CAPTEM.<p clas...